Report Store Get Proposal

Home Blog Notizia 39

Notizia - Recent Pharma, Healthcare and Biotech Happenings

recent-pharma-biotech-news-updates-happenings-for-beam-grail-quest-diagnostics

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Beam adds to drug delivery stable with USD 120 Million GuideTx buy Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Beam announced that it paid USD 120 million upfront to acquire Guide Therapeutics in an all-stock agreement. The gene-editing technologies, which have reached the clinic, CRISPR, zinc finger nucleases, and TALENs, make their edits by nicking DNA at the target site. Cambridge, Massachusetts-based Beam aims to make more precise edits with genetic medicines, which employ base-editing. Instead of snipping the genome...

Explore More...

MERCK ONCOLOGY

Oncology Highlights – 30/07/2018

transthyretin amyloidosis

Notizia

transthyretin amyloidosis

Idera’s drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates

transthyretin amyloidosis

Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation

Notizia

Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating

Entasis

Business Cocktail

transthyretin amyloidosis

Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod

Default Blog Image

Horizon Discovery declines Abcam’s USD 367 million takeover bid

transthyretin amyloidosis

Notizia

transthyretin amyloidosis

Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients

Default Blog Image

Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs

BioGen

Business Cocktail

BioGen

Business Cocktail

transthyretin amyloidosis

Notizia

BioGen

Business Cocktail

Notizia

Notizia

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly